Reimagining RNA medicine

Oct 20, 2026

Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026

Oct 19, 2026

Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026

Oct 13, 2026

Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference

Oct 01, 2026

Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD

Sep 30, 2026

Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

Sep 23, 2026

Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity

Sep 22, 2026

Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer

Sep 03, 2026

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

Aug 10, 2026

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

Aug 05, 2026

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware